226
Views
10
CrossRef citations to date
0
Altmetric
Original Research

Real-World Efficacy and Safety of Mycophenolate Mofetil in Active Moderate-to-Sight-Threatening Thyroid Eye Disease

, , & ORCID Icon
Pages 1921-1932 | Published online: 10 May 2021

Figures & data

Table 1 Demographics and Baseline Characteristics of Our Cohort of 20 Individuals

Figure 1 Duration of mycophenolate mofetil treatment for 20 patients.

Figure 1 Duration of mycophenolate mofetil treatment for 20 patients.

Figure 2 Flowchart demonstrating the treatments received by individuals with moderate-severe TED and those with DON at baseline, 24 weeks, 52 weeks and 78 weeks.

Figure 2 Flowchart demonstrating the treatments received by individuals with moderate-severe TED and those with DON at baseline, 24 weeks, 52 weeks and 78 weeks.

Table 2 Ophthalmic Assessments for Individuals with Moderate-Severe TED and Sight-Threatening DON at Baseline, 24 Weeks, 52 Weeks, 78 Weeks

Table 3 Ophthalmic Responses for Individuals with Moderate-Severe TED and Individuals with Sight-Threatening DON at 24 Weeks, 52 Weeks, 78 Weeks vs Baseline

Table 4 Relapses in Those with Moderate-Severe TED and Sight-Threatening DON Occurring by 24 Weeks, 52 Weeks, 78 Weeks

Table 5 Side Effects During Mycophenolate Mofetil Treatment for Our Cohort